SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...

Eli Lilly has shared positive two-year results from an open-label extension (OLE) study of Omvoh (mirikizumab-mrkz) in active ...

Eli Lilly has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to ...

Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...

SAN FRANCISCO -- Janus kinase (JAK) inhibitors appeared to be a safe, effective option for treating inflammatory bowel ...

Medically reviewed by Robert Burakoff, MD Irritable bowel syndrome (IBS) is a combination of digestive symptoms, including ...

Severe abdominal pains, unpredictable bowel movements and fatigue are some of the serious symptoms 180,000 Australians live ...

In particular, he said that the drug had achieved improvements in endoscopic and histologic biomarkers of ulcerative colitis, noting that “can be difficult to achieve.” The results weren’t a ...

Older adults with moderate to severe IBD can achieve remission with JAK inhibitors, according to a study presented at Crohn’s & Colitis Congress.

Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as ... symptomatic, endoscopic and histologic endpoints ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...